Single Centre Drug-Drug Interaction study with Levothyroxine/Magnesium-Citrate and Levothyroxine/Magnesium-Aspartate in healthy subjects

niversity Hospital of Zurich0 个研究点目标入组 12 人开始时间: 2023年10月17日最近更新: 2023年10月30日

适应症

试验速览

暂无简介。

•1. Contraindications to the drugs under study, e.g. known hypersensitivity or allergy
•2. Need for any kind of drug therapy for the duration of the study
•3. Women who are pregnant or breastfeeding
•4. Intention to become pregnant during the course of the study
•5. Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration. Female participants who are surgically sterilised / hysterectomized or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
•6. Other clinically significant concomitant disease states (e.g., renal failure, thyroid dysfunction, cardiovascular disease, arterial hypertension, any other medical condition that could lead to an albumin deficiency such as anorexia etc.)
•7. Abnormal findings in the screening tests (laboratory, ECG, physical examination).
•8. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
•9. Participation in another study with investigational drug within the 30 days preceding and during the present study
•10. Previous enrolment into the current study
•11. Enrolment of the investigator, his/her family members, employees and other dependent persons

发起方

niversity Hospital of Zurich